Art

J-GLOBAL ID：201702224969752115   Reference number：17A0552215

Increase in the systemic exposure of primary metabolites of Midazolam in rat arising from CYP inhibition or hepatic dysfunction

ラットにおいてCYP阻害または肝機能不全により生じたミダゾラムの一次代謝物の全身曝露増加

Author (7)： Hasegawa Tsubasa (Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan) ,  Nakanishi Satomi (Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan) ,  Minami Keiko (Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan) ,  Higashino Haruki (Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan) ,  Kataoka Makoto (Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan) ,  Shitara Yoshihisa (Pharmacokinetics, Dynamics and Metabolism, Sanofi K.K., Tokyo, Japan) ,  Yamashita Shinji (Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan)
Material： Drug Metabolism and Pharmacokinetics (Web)  (Drug Metab Pharmacokinet (Web))
Volume： 32  Issue： 1  Page： 69-76  Publication year： Feb. 2017 
JST Material Number： U0705A  ISSN： 1347-4367  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Thesaurus term： *cytochrome P450 ,...
Semi thesaurus term： hepatic insufficiency ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0552215&from=J-GLOBAL&jstjournalNo=U0705A") }}

Author keywords (6)： Midazolam ,  Primary metabolites ,  Systemic exposure ,  Drug-drug interaction ,  CYP inhibition ,  Acute hepatitis

JST classification (2)： Physicochemical characteristics of drugs  (GV01060M) ,  Basic research of psychotropic drugs  (GW03100Y)

Substance index (5)： Midazolam ,  1H-Benzotriazol-1-amine ,  4-Hydroxymidazolam ,  1-Hydroxymidazolam ,  Carbon Tetrachloride

Reference (42)：

• Riss PJ, Rosch F. A convenient chemo-enzymatic and 18F-labelling of both enantiomers of trans-1-toluenesulfonyloxymethyl-2-fluoromethly-cyclopropane. Org Biomol Chem 2008;6:4567-74.
• Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001;357:1870-5.
• Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306.
• Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 2006;21:347-56.
• Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl Med 1998;338:916-7.

Terms in the title (8)： ラット ,  CYP ,  阻害 ,  肝機能不全 ,  ミダゾラム ,  一次代謝物 ,  全身 ,  曝露